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Abstract: Background: The biological mechanisms that contribute to atrophic long bone non-union
are poorly understood. Multipotential mesenchymal stromal cells (MSCs) are key contributors to bone
formation and are recognised as important mediators of blood vessel formation. This study examines
the role of MSCs in tissue formation at the site of atrophic non-union. Materials and Methods: Tissue
and MSCs from non-union sites (n = 20) and induced periosteal (IP) membrane formed following
the Masquelet bone reconstruction technique (n = 15) or bone marrow (n = 8) were compared. MSC
content, differentiation, and influence on angiogenesis were measured in vitro. Cell content and
vasculature measurements were performed by flow cytometry and histology, and gene expression
was measured by quantitative polymerase chain reaction (qPCR). Results: MSCs from non-union sites
had comparable differentiation potential to bone marrow MSCs. Compared with induced periosteum,
non-union tissue contained similar proportion of colony-forming cells, but a greater proportion
of pericytes (p = 0.036), and endothelial cells (p = 0.016) and blood vessels were more numerous
(p = 0.001) with smaller luminal diameter (p = 0.046). MSCs showed marked differences in angiogenic
transcripts depending on the source, and those from induced periosteum, but not non-union tissue,
inhibited early stages of in vitro angiogenesis. Conclusions: In vitro, non-union site derived MSCs
have no impairment of differentiation capacity, but they differ from IP-derived MSCs in mediating
angiogenesis. Local MSCs may thus be strongly implicated in the formation of the immature vascular
network at the non-union site. Attention should be given to their angiogenic support profile when
selecting MSCs for regenerative therapy.
Keywords: MSCs; fracture healing; non-union; induced periosteum; osteogenesis; regenerative
medicine
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1. Introduction
Non-union (NU) occurs in approximately 10% of long bone fractures, with an incidence of
approximately 19 per 100,000 population per annum in the developed world, and is associated
with considerable morbidity, expenditure, and social cost [1,2]. NU can be broadly classified into
either hypertrophic or atrophic based on characteristic radiological features [3,4]; while it is widely
accepted that inadequate mechanical fixation is the primary contributing factor to the development of
hypertrophic NU [5–7], the causes of atrophic NU are less well understood.
The probability that any fracture will develop into atrophic NU is dependent on multiple factors
including loss of bone at the fracture site, infection, extensive soft tissue damage, and open fractures [8,9].
Patient specific factors such as age; gender; the administration of non-steroidal anti-inflammatory
drugs; smoking; and medical comorbidities including anaemia, diabetes, and hormone disorders
as well as genetic factors have also been suggested to contribute to NU risk [8,9]. Despite these
observations, reliable predictive measures of those at risk of NU are not available and the nature of the
underlying biological mechanisms is poorly understood.
Mesenchymal stromal cells (MSCs) are widely accepted as being key contributors to new bone
formation following fracture, and in surgery are often taken from bone marrow (BM) and used as
components of autologous grafts [10,11]. Indeed, the use of autologous MSCs for the treatment of NU
is well established and widely practiced [10,12–15]. Recently, there has also been a great deal of interest
in the ability of MSCs to act as regenerative agents independently of their ability to directly form new
tissue [16–19]. Several studies in the field of ischaemic heart injury have investigated their ability
to act as mediators of angiogenesis by the release of trophic factors, including vascular endothelial
growth factor (VEGF) [19–21]. The relationship between MSCs and blood vessels has been the subject
of much interest, and some have suggested that all MSCs are in fact pericytes [22–24]. Regardless of the
answer to this question, it is clear that MSCs are closely associated with blood vessels and, therefore,
interactions between MSCs and endothelial cells may be of crucial importance in physiological healing.
Historically, it was suggested that vascularity of the NU site was a key difference between
hypertrophic and atrophic NU, with some suggesting atrophic NUs to be avascular and essentially
inert [25]. However, this pre-conception has been challenged by several publications which found
significant vascularity in atrophic tissue [25–27]. An alternative hypothesis could be that atrophic
NU tissue lacks the required regenerative cells, or that regenerative cells are present but lack potency.
This was supported by the work of Bajada et al., who confirmed that although MSCs are present at the
site of atrophic NU, they had reduced osteogenic potential and increased cell senescence compared
to those isolated from BM [26]. However, it must be noted that MSCs in the bone marrow may be
fundamentally different from those in peripheral tissues, not least in their well described role in
maintaining the haematopoietic niche [28–30], a property which has not been demonstrated for MSCs
resident in other tissues.
The Masquelet technique is a form of guided bone regeneration used for the repair of large bone
defects [31,32]. In the first stage, a membrane is formed following the implantation of a cement spacer.
The cement is subsequently removed and replaced with autologous bone graft, leaving the membrane
in place [33]. Karger et al. reported healing defects larger than 10 cm using this technique and union
was achieved in an average of nine months with a success rate of 94% [34]. Moreover, time to union
was not dependent on defect size [34]; this is important given that defects of up to 25 cm have been
repaired using this technique [35].
These impressive results have generated interest in the properties of the membrane formed;
indeed, it has been shown to possess osteogenic, osteoinductive, and angiogenic properties [33,36,37].
We recently reported characteristics very similar to periosteum in terms of thickness, cellularity,
and anatomical location [38], leading us to coin the phrase “induced periosteum” (IP). Additionally,
IP contained a far greater frequency of MSC than reported in BM aspirates [38–41], and MSCs
isolated from the IP were functionally equivalent to those isolated from matched normal periosteum,
a well-accepted source of MSCs with osteogenic potential comparable to those isolated from bone
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marrow [42–45]. To date, no studies have addressed the fundamental difference in MSC function
between atrophic NU tissue and tissue from a site of high osteogenic potential. In this study, we examine
the cellular content, histological characteristics, and vascularity of NU and IP tissue, as well as the
angiogenic potential of MSCs isolated from these tissues. Multipotent differentiation potential of NU
MSCs was compared with the standard BM MSCs.
2. Materials and Methods
2.1. Patient Recruitment
This work was performed at Leeds Institute of Rheumatic and Musculoskeletal Disease, University
of Leeds, and Department of Pharmacy, School of Health Sciences, University of Patras. Study
participants were patients admitted for treatment of atrophic NU fractures, critical size defects using
the induced membrane technique, or elective orthopaedic surgery to either the upper or lower extremity.
All patients gave informed consent and research was carried out in compliance with the Helsinki
Declaration. Ethical approval was obtained from the U.K. Health Research Authority, Leeds East
Research Ethics Committee for the harvesting of these tissues.
In total, 20 patients suffering from fracture NU (median age: 53, range 23–81, 11 males: 9 female)
and 15 patients treated for critical size defects using the induced membrane technique (median age 61,
range 19–80, 10 male: 5 female) were recruited. Bone marrow (BM) aspirates were collected from eight
patients undergoing elective orthopaedic surgery (median age 38, range 19–52, 3 males: 5 female).
2.2. Tissue Collection and Processing
Fibrotic NU tissue was collected directly from the NU site. At the time of surgery, following
exposure of the fracture site, the fibrotic tissue lying directly between the fractured bone fragments
was excised and collected for study.
Samples for the IP were collected at a mean time of 7.6 weeks (range 6–9) from the first stage of the
technique (insertion of cement spacer). Approximately 1 cm of membrane tissue was harvested from
the center of the bone defect area. Tissue was either digested by incubation in collagenase solution to
generate a single cell suspension for culture initiation or flow cytometry analysis, or processed for
histology [38]. A subset of samples tissue was bisected for both enzymatic digestion and processing for
histology. BM aspirates were seeded directly in culture in StemMACS media (Miltenyi Biotec, Bisley,
Surrey, UK) with penicillin and streptomycin (Thermo Fisher Scientific, Paisley, UK) to generate BM
MSC cultures, as previously described [38].
2.3. Colony Forming Potential
A colony forming unit fibroblast (CFU-F) assay was used to assess MSC content in enzymatically
digested NU and IP tissues [38]. A total of 1 × 104 cells were seeded in duplicate into 10 cm diameter
tissue culture plates (Corning B.V. Life Sciences, Amsterdam, The Netherlands) and incubated in
StemMACS media with penicillin and streptomycin in standard culture conditions for 14 days,
followed by fixation in 4% formalin solution (Sigma Aldrich, Gillingham, Dorset, UK) and staining with
methylene blue (Sigma Aldrich). Colonies were defined as ≥50 tightly clustered cells. BM aspirates
were seeded volumetrically directly in culture in StemMACS media, as previously described [39].
2.4. In Vitro Osteogenesis, Chondrogenesis, and Adipogenesis
Enzymatically released cells from the NU tissue were incubated in standard culture conditions in
StemMACS media. After 48 h, the culture media was renewed and expansion continued for 14 days
with twice weekly half media changes. Subsequently, cells were trypsinised and re-seeded at a density
of 4500 cells/cm2 and expansion continued for a maximum of two passages. For these experiments,
BM MSCs were expanded similarly and used as control. Both types of cultures were seeded into
differentiation assays at the same seeding density, as previously described [38]. Measurement of
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alkaline phosphatase activity was assessed at 14 days after the initiation of osteogenic culture conditions,
as previously described [46,47]. The degree of mineralisation, by measurement of calcium, was carried
out at 21 days post initiation. For chondrogenic assays, ChondroPrime SF media (PAA laboratories,
GE Healthcare, Chicago, IL, USA) was used, over a period of 21 days [46,47]; cell pellets were visualised
after staining with Toludine blue solution [38] using an Eclipse E1000 light microscope (Nikon, Kinston
upon Thames, Surrey, UK). For adipogenic assays, cells were seeded into NH adipoDiff medium
(Miltenyi Biotec) and cultured, over 21 days [46,47], followed by staining with oil red O (Sigma) as
previously described [38]. Images were captured using a CKX41 inverted light microscope (Olympus,
Southend on Sea, UK).
2.5. Histology and Immunohistochemistry
Histology and immunohistochemistry (IHC) were carried out on paraformaldehyde-fixed
histological IP and NU tissue sections (n = 8 and 9 respectively). Haematoxylin and eosin staining
was performed according to standard protocols. IHC staining was carried out using EnVision
peroxidase/DAB+ detection system (Dako, Stockport, UK) and specific anti-human antibodies
(Supplementary Table S1). In cases where antigen retrieval was required, this was performed by heating
sections in boiling 10 nM citrate buffer (pH 6.0) in a 900 W microwave oven for 10 min. All images
were captured using an Eclipse E1000 light microscope (Nikon). For measurement of average blood
vessel size, up to six photomicrographs (dependent on tissue size) were taken at 200×magnification
following CD31 labelling. Measurement of blood vessel areas was then performed blinded using
ImageJ free access image processing and analysis software available from http://rsb.info.nih.gov/ij/.
The number of vessels was counted in at least 20 different random fields of each experimental group,
as previously described [48]. Analysis of CD45, stromal-derived factor 1 (SDF1), vascular endothelial
growth factor 1 (VEGF), and bone morphogenetic protein 2 (BMP-2) expression was performed using
NIS elements BR (Nikon Instruments Inc., Melville, USA ) image analysis software.
2.6. Flow Cytometry
Enzymatically digested single cell suspensions were incubated with specific fluorescently labelled
primary antibodies for 30 min at 4 ◦C at manufacturer recommended concentrations (Supplementary
Table S1). Cells were then washed and incubated with 4’,6-diamidino-2-phenylindole to assess viability,
and then analysed using a LSR II flow cytometer (BD) and FacsDiva analysis software (BD, Oxford, UK).
The proportions of pericytes of (CD45-CD34-CD146+) [49], endothelial cells of (CD45-CD31+) [40],
and lymphocytes of (CD45+ low side-scatter) [40] were measured.
2.7. Quantitative Real-Time PCR (qPCR)
A 48-gene array was employed, focusing predominantly on markers of angiogenesis as well as
common MSC lineage (chondro-, adipo-, osteo) markers [50]; for a full list of genes, see Supplementary
Table S2. IP and NU derived MSCs (n = 7 and 8, respectively) were cultured up to passage 2, before
being trypsinised and washed. Control unmatched, expanded (p2) iliac crest BM MSCs (n = 8) and skin
fibroblast cell lines (n = 3, Lonza and ATCC) were also prepared. Cells were lysed and RNA isolated
using Norgen Total RNA Isolation Kit (Geneflow, Lichfield, UK). cDNA was produced using High
Capacity cDNA reverse transcription kit for use on the Taqman low density array (TLDA) with 2×
gene expression mix (all Thermo Fisher) [50]. Further individual Taqman assays were used to analyse
additional transcripts and for validation of the TLDA. All gene expression analysis was using the
2−∆Ct method, normalised to HPRT. Greater than two-fold expression change was considered different,
when significant.
2.8. In Vitro Angiogenesis
Matrigel-based angiotube formation assay was performed to assess the paracrine angiogenic
potential of IP and NU MSCs. MSCs originating from IP and NU tissue were seeded in cell culture
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flasks (Corning Inc., New York, NY, USA) and incubated under standard conditions in MSC growth
media (StemMACS Media). At 80% confluence, supernatant was removed and new MSC growth
media was added, as previously described [51]. Following a further 72 h incubation, MSC conditioned
media was centrifuged at 300× g for 10 min to eliminate dead cells and debris, and the supernatant
was then frozen at −80 ◦C until use. The MSCs from each flask were trypsinized and counted to allow
standardization on a per cell basis.
Then, 2 × 104 human umbilical vein endothelial cells (HUVECs; Lonza, Basilea, Switzerland)
were seeded on Matrigel (Corning Inc.) pre-coated 96-well culture plates (Corning Inc.). Endothelial
cells were incubated in MSC conditioned media, HUVEC medium (endothelial cell growth medium 2;
PromoCell, Heildelberg, Germany) was used as a positive control and unconditioned MSC growth
medium was used to assess baseline angiogenesis. All conditions were assessed in duplicate
and two images per well were taken after 3 h, using a Cytation 5 imaging plate reader (BioTek,
Winooski, VT, USA).
Images were analyzed using the macro Angiogenic Analyzer for ImageJ software. We compared
the results from the two cell types, as described by Khoo et al. [52], by calculating the number of
junctions, number of tubules, and tubule length. Data obtained were normalized to 1 × 106 cells
and expressed as percentage of change fold, compared with unconditioned MSC growth medium.
Supplementary Table S3 summarises control tissues used throughout the study.
2.9. Statistical Analysis
The Mann-Whitney U test was used to determine the statistical significance for all comparisons
between BM and NU and IP and NU samples. SPSS version 21 (IBM, New York, NY, USA) was
used for statistical analysis throughout, while GraphPad Prism version 7.02 (GraphPad Software Inc.,
La Jolla, CA, USA) was used to generate all graphs. All quantitative measurements were performed in
triplicate (technical replicates) and the biological replicates (donor numbers) are specified in each figure
legend. Box plots displayed as median (line), interquartile range (box) and extreme values (whiskers).
3. Results
3.1. Colony Formation and Differentiation Capacity of Resident MSCs
To investigate if NU tissue contained MSCs, CFU-F assays were undertaken on NU tissue digests
and their trilineage differentiation capacity was compared with BM MSCs that are commonly used as
the standard control for the assessment of MSC colony-forming ability and multipotentiality (Figure 1).
Following enzymatic digestion and in vitro cultivation, cells isolated from NU tissue readily formed
colonies (Figure 1A, left panel) similar to MSCs from BM aspirates (Figure 1A, right panel). In vitro
expansion of colony forming cells followed by induction of differentiation in osteogenic, chondrogenic,
and adipogenic media showed that cells from NU tissue were capable of osteogenic, chondrogenic,
and adipogenic differentiation, as shown by positive alkaline phosphatase staining, toluidine blue, and
oil red O staining, respectively (Figure 1B–D, top panels), compared with NU-derived cells grown in
normal growth media (Figure 1B–D, bottom panels). Quantitative measurement of chondrogenesis
by glycosaminoglycan (GAG) accumulation showed parity between NU- and BM-derived MSCs
(Figure 1E), as did quantitative measurement of osteogenesis by calcium accumulation (Figure 1F).
These data indicated that NU tissue had cells with robust in vitro MSC activity.
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Figure 1. Colony formation (A) and multi-lineage differentiation potential (B–E) of non-union
(NU)-derived mesenchymal stromal cells (MSCs). Enzymatically digested non-union tissue readily
forms similar-sized colonies in vitro (A, left panel) compared with control MSCs derived from
bone marrow (BM) aspirates (A, right panel). Culture expanded adherent cells undergo osteogenic
differentiation, as shown by alkaline phosphatase staining (B); chondrogenic differentiation, as shown
by toluidine blue staining of chondrogenic pellets (C); and adipogenic differentiation, as shown by oil
red staining (D). The bottom panels on B–D show cells stained after culturing in normal growth media.
Quantitative measurements of chondrogenesis, measured by glycosaminoglycan (GAG) accumulation
(E), and osteogenesis, measured by accumulation of Ca2+ (F), were comparable between BM MSCs
(BM) (n = 6) and non-union derived MSCs (NU) (n = 6).
3.2. Cellular Composition of NU Tissue
To investigate the frequency of MSCs, as well as other cells important in the bone repair process
in NU t ssue, CFU-F assay and flow cytometry using NU tissue digests were perform d, and the data
were compared to IP tissue, which is known to be an active reservoir of such c lls [38]. IP was chosen
as the ost appropriate positive contr l i these experiments because, similarly to NU tissue, it is
newly-formed and v scularised in vivo during the regenerative process of fracture healing. Resident
MSCs were measured using CFU-F assay and flow cytometry for cells expressing phenotypic markers
consistent with pe icytes [38]. Colony forming potential of NU and IP tissu measur d by CFU-F assay
wa comparable (Figur 2A), indicating no significant d fference in MSC content between these tissues.
However, the NU tissue contained a sign ficantly greater perc ntag of cells expr ssing ph otypic
markers c nsistent with pericyt s: NU ha a median of 13.8% pericytes (ran e 9.2–45.7) compared
with 4.9% in IP tis ue (range 0.3–15.1, p = 0.036, Figure 2B), indicating a ossible accumulation of
pericyt s, but not MSCs in the NU tissue. NU tissue also contained a greater percentage of CD31+
endothelial cells; NU had a median proport on of 18.2% endothelial cells (r nge 10.1–53.1) comp r d
with 5.5% in IP (range 1.7–19.8, p = 0.016, Figure 2C). Finally, NU tissue had a reduced number of
lymphocytes; NU had a median propo tion of 6.8% lymphocytes (rang 1.3–15.1) compared with 22.2%
(rang 4.4–71.1, p = 0.007) in IP (Figure 2D). Supplementary Figure S2E de onstra the original flow
cytometry plots for these cell populations. These data provided a first indication fo the disturbed
MSC–pericyte r lat onship in the NU tissue.
J. Clin. Med. 2020, 9, 1628 7 of 17
J. Clin. Med. 2020, 9, x 7 of 16 
 
 
Figure 2. A comparison of cellular composition between NU and induced periosteum (IP) tissue. 
Comparison of the percentage of colony forming cells assessed by colony forming unit fibroblast 
(CFU-F) assay following enzymatic digestion and in vitro culture in induced periosteum (IP) (n = 8) 
and non-union (NU) tissue (n = 6) (A). Flow cytometry analysis of the percentage of cells expressing 
cell surface markers consistent with pericytes (CD45-CD34-CD146+) (B), endothelial cells (CD45-
CD31+) (C), and lymphocytes (CD45+side scatter low) (D), following enzymatic digestion of IP (n = 10) 
and NU tissue (n = 6). * denotes p < 0.05, ** denotes p < 0.01. 
3.3. Histological Comparison of NU and IP Tissue 
To investigate whether disparities in the observed numbers of pericytes, MSCs, and endothelial 
cells were related to different abundance of blood vessels in these tissues, IHC for CD31 was 
performed. By blinded manual measurement of blood vessel internal area, IP was found to contain a 
greater number of larger calibre blood vessels in comparison with NU tissue (Figure 3A), where we 
also noted the presence of several clusters of small calibre vessels. This observation was confirmed 
by blinded manual measurement of blood vessel internal area; median vessel area per sample in IP 
tissue was approximately 2.9-fold greater than that of NU tissue (500 µm and 174 µm, respectively, p 
= 0.046, Figure 3A). Alternative analysis by comparison of individual vessel size for each tissue type 
was highly significant (Supplementary Figure S1A) and analysis of vessel density showed a 2.4-fold 
increase in the number of vessels per field in NU compared with IP tissue (p = 0.001, Figure 3A). 
Together, these results and the abundance of endothelial cells measured by flow cytometry suggest 
differences in both blood vessel size and number. Moreover, consistent with flow cytometry data, 
CD45 staining for the presence of leukocytes showed a far greater abundance of tissue-resident 
leukocytes throughout IP in comparison with NU tissue (Figure 3B). This was confirmed by 
automated quantitative scoring of the proportion of area occupied by CD45 positively stained cells. 
The median CD45 positive area in IP was 2.2% (range 0.56–10.06) compared with 0.4% (range 0.15–
1.68) in NU tissue (p = 0.005, Figure 3B). This was consistent with our flow cytometry data showing 
higher percentages of CD45+ lymphocytes in IP tissue compared with NU tissue, as shown on Figure 
2D. Immunohistochemical analysis of NU tissue confirmed the presence of SDF-1, VEGF, and BMP-
2 and their localisation to blood vessels (Figure 3C); this was consistent with our previous findings 
in IP tissue [38]. Haematoxylin and Eosin staining of NU tissue showed the presence of small 
fragments of dead bone, shown by their lack of viable osteocytes (Supplementary Figure S1B), 
suggesting inadequate clearance by osteoclasts. 
Figure 2. A comparison of cellular composition between NU and induced periosteum (IP) tissue.
Comparison of the percentage of colony forming cells assessed by colony forming unit fibroblast
(CFU-F) assay following enzymatic digestion and in vitro culture in induced periosteum (IP) (n = 8)
and non-union (NU) tissue (n = 6) (A). Flow cytometry analysis of the percentage of cells expressing cell
surface markers consistent with pericytes (CD45−CD34−CD146+) (B), endothelial cells (CD45−CD31+)
(C), and lymphocytes (CD45+side scatter low) (D), following enzymatic digestion of IP (n = 10) and
NU tissue (n = 6). * denotes p < 0.05, ** denotes p < 0.01.
3.3. Histological Comparison of NU and IP Tissue
To investigate whether disparities in the observed numbers of pericytes, MSCs, and endothelial
cells were related t different abundance of blood vessels in these tissues, IHC for CD31 was performed.
By blin ed ma ual eas re nt of blood vessel internal ar a, IP w s found t contain a greater
number of larger calibre blood vessels in comparison with NU tissue (Figure 3A), where we also noted
the pr sence of several clust rs of small calibre vessels. This observati n was confirmed by blin ed
ma ual me s rement of blood vessel internal area; median vessel area per sampl in IP tissue was
approximately 2.9-fold greater than that of NU tissue (500 µm and 174 µm, respectively, p = 0.046,
Figure 3A). Alternative analysis by comparison of individual vessel siz for each tissue type was highly
significant (Supplementary Figure S1A) and analysis of vessel density showed a 2.4-fold increase in
th number of vessels per field in NU compared with IP tissue (p = 0.001, Figure 3A). Togeth r, these
results and the abund ce of endothelial cells measured by flow cytometr suggest differences in both
blood vessel size and number. Moreover, consistent with flow cytometry data, CD45 staining for the
presence of leukocytes showed a far greater abundance of tissue-resident leukocytes throughout IP in
comparison with NU tissue (Figure 3B). This was confirmed by a tomated quantitative scoring of the
proportion of are occupied by CD45 ositively stained cells. The median CD45 positive rea in IP was
2.2% (range 0.56–10.06) comp red with 0.4% (range 0.15–1.68) in NU tissu (p = 0. 05, Figure 3B). This
was consistent with our flow cytometry data showing higher percentages of CD45+ lymphocytes in IP
tissue compared with NU tissue, as shown on Fig re 2D. Immunohistochemical analysis of NU tissue
confirmed the presence of SDF-1, VEGF, and BMP-2 and their localisation to blood vessels (Figure 3C);
this was c nsistent with our pr vious findings in IP tissue [38]. Haematoxylin and Eo in staining
of NU tissue show d the presence of small fragments of dead bone, shown by their lack of vi ble
osteocytes (Supplementary Figure S1B), suggesting inadequate cl arance by osteoclasts.
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staining per field (right) (B). Higher magnification images of CD45+ cells in IP and NU tissue are 
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Figure 3. Histological examination of NU tissue. Comparison of blood vessel size highlighted by
immunohistochemistry (IHC) staining for CD31 expression in induced periosteum (IP) and non-union
(NU) tissue, representative photomicrographs (200×magnification, scale bar 100µm) showing blood
vessels (left and middle panels), comparison of mean internal vessel area by manual blind scoring (top
right), and comparison of mean number of blood vessels per field (bottom right) (A). Comparison of
leukocyte content highlighted by IHC staining for CD45 expression in IP and NU tissue, representative
photomicrographs (200×magnification, scale bar 100 µm) showing leukocyte content (left and middle
panels), and automated comparison showing the average area of positive staining per field (right) (B).
Higher magnification images of CD45+ cells in IP and NU tissue are shown in the inserts. IHC staining
highlighting perivascular location of stromal-derived factor-1 (SDF-1), vascular endothelial growth
factor (VEGF), and bone morphogenetic protein-2 (BMP-2) in NU tissue (scale bar 30 µm) (C). All data
IP (n = 8) and NU tissue (n = 9), arrows show regions of positive staining (brown). * denotes p < 0.05,
*** denotes p ≤ 0.001.
3.4. Transcriptional Profile Comparison of IP and NU Derived MSCs
The combined colony forming potential, IHC, and flow cytometry data indicated that, while
MSCs were abundant in NU tissue, the proportion of endothelial cells, pericytes, and lymphocytes,
as well as blood vessel diameters and density, differed. As MSCs are known to participate in tissue
formation and remodelling via their trophic functions of chemo-attraction and angiogenic support
activity [16–19], we investigated the expression of possible mediators of these activities, using a 48-gene
array encompassing genes involved in tissue formation and angiogenesis. This was performed on
NU MSCs and compared with BM MSCs (positive control), skin fibroblasts (negative control), and IP
MSCs, with the latter representing MSCs from a highly-osteogenic environment (Figure 4). Cluster
analysis of 48-gene TLDA data showed tight clustering of fibroblasts away from IP, NU, and most
BM-derived MSCs. BM MSCs flanked IP and NU MSC profiles, while IP and NU MSCs clustered
together with no obvious separation from each other (Figure 4A).
Comparison of the expression of individual transcripts between IP- and NU-derived MSCs and
control BM MSCs showed interesting trends. Among genes with predominantly endothelial regulatory
roles, expression of FLT1 and ANGPTL4 was lower in NU tissue compared with both BM MSCs and
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IP MSCs. These differences were statistically significant when NU MSCs were compared with IP
MSCs (p = 0.021 and p = 0.012 respectively, Mann–Whitney U test). MCAM1 expression was similarly
higher in NU MSCs compared with IP MSCs, although short of significance (p = 0.059), whereas
PTN was significantly increased in NU (p = 0.003, Mann–Whitney U test) compared with IP tissue
(Figure 4B). Expression of Wnt pathway genes FZD4 and WNT2 was decreased in NU MSCs compared
with IP MSCs (p = 0.016 and 0.028 respectively, Mann–Whitney U test) (Figure 4B). We did not observe
any significant difference in other Wnt related genes, including DKK1, DKK2, SOST, and KREMEN1.
Expression of SOX9 and BMP-2 both involved in MSC differentiation were increased in NU tissue
MSC compared with IP MSCs; however, this only reached significance in the case of SOX9 (p = 0.012,
Mann-Whitney U test) (Figure 4B).
J. lin. Med. 2020, 9, x 9 of 16 
 
similarly higher in NU MSCs compared with IP MSCs, although short of significance (p = 0.059), 
whereas PTN was significa tly increased in NU (p = 0.003, Mann–Whitney U test) compared with IP 
tissue (Figure 4B). Expression of Wnt pathway genes FZD4 and WNT2 was decreased in NU MSCs 
compared with IP MSCs (p = 0.016 and 0.028 respectively, Mann–Whitney U test) (Figure 4B). We did 
not observe any significant difference in other Wnt related genes, including DKK1, DKK2, SOST, and 
KREMEN1 (data not shown). Expression of SOX9 and BMP-2 both involved in MSC differentiation 
were increased in NU tissue MSC compared with IP MSCs; however, this only reached significance 
in the case of SOX9 (p = 0.012, Mann–Whitney U test) (Figure 4B). 
 
Figure 4. Differentially expressed transcripts in MSCs derived from IP and NU tissue. Cluster analysis 
of log 2 transformed relative expression data: 2−ΔCt normalised to HPRT. IP—induced periosteum (n 
= 7), NU—non-union (n = 8), BM—bone marrow (n = 8), and Fib—skin fibroblasts negative control (n 
= 3). Green < HPRT, red > HPRT, black = HPRT, and grey is missing data. Genes were analysed when 
80% present, complete linkage clustering was performed and viewed using Java Treeview (A). Genes 
showing marked differences in relative expression between NU MSCs and IP MSCs; BM MSCs 
included as controls. Genes involved in regulation of endothelial cells (FLT1, PTN, ANGPL4, and 
MCAM), Wnt signalling genes (FZD4 and WNT2), and genes involved in MSC differentiation (SOX9 
and BMP-2) (B). All data IP (n = 7), NU (n = 8), BM (n = 8). R.E.U.—relative expression unit. 
3.5. Assessment of MSC Mediated Angiogenesis 
To understand the functional effect of differences in transcriptional expression between MSCs 
originating from IP and NU tissue, a matrigel-based angiotube formation assay that reflects the early 
stages of angiogenesis was performed [51,52], using conditioned IP- and NU-MSC growth media. 
Some angiogenesis was observed using unconditioned MSC growth media; therefore, this was used 
as a baseline and the contribution of MSC conditioning was standardised against this (data not 
shown). There was striking inhibition of in vitro angiogenesis in media conditioned with IP origin 
MSCs compared with NU origin MSCs. Several parameters were assessed: the total tube length 
(Figure 5A) and the total number of tubes formed (Figure 5B). In all cases, conditioned media from 
IP MSCs had a significant negative effect on early angiogenesis compared with NU-derived MSCs 
Figure 4. Differentially expressed transcripts in MSCs derived from IP and NU tissue. Cluster analysis
of log 2 transformed relative expression data: 2−∆Ct normalised to HPRT. IP—induced periosteum
(n = 7), NU—non-union (n = 8), BM—bone marrow (n = 8), and Fib—skin fibroblasts negative control
(n = 3). Green < HPRT, red > HPRT, black = HPRT, and grey is missing data. Genes were analysed
when 80% pr sent, complete linkage clustering was performed and viewed using J va Tre view (A).
Genes showing marked differences in relativ expression between NU MSCs an IP MSCs; BM MSCs
included as controls. Genes involved in regulation of endothelial cells (FLT1, PTN, ANGPL4, and
MCAM), Wnt signalling genes (FZD4 and WNT2), and genes involved in MSC differentiation (SOX9
and BMP-2) (B). All data IP (n = 7), NU (n = 8), BM (n = 8). R.E.U.—relative expression unit.
3.5. Assessment of MSC Mediated Angiogenesis
To understand the functional effect of differences in transcriptional expression between MSCs
originating from IP and NU tissue, a matrigel-based angiotube formation assay that reflects the early
stages of angiogene is was performed [51,52], using conditioned IP- a d NU-MSC growth media.
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Some angiogenesis was observed using unconditioned MSC growth media; therefore, this was used as
a baseline and the contribution of MSC conditioning was standardised against this. There was striking
inhibition of in vitro angiogenesis in media conditioned with IP origin MSCs compared with NU origin
MSCs. Several parameters were assessed: the total tube length (Figure 5A) and the total number of
tubes formed (Figure 5B). In all cases, conditioned media from IP MSCs had a significant negative effect
on early angiogenesis compared with NU-derived MSCs (all p = 0.001). These effects are illustrated by
photomicrographs of endothelial tube formation taken at the end-point of this assay (Figure 5C).
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Figure 5. MSC from induced periosteum inhibit early in-vitro angiogenesis. Angiogenesis measured
by total tube length (A) and total number of tubes (B) shows a significant inhibitory effect of media
conditioned by MSCs originating from induced periosteum (IP) compared with non-union (NU) and
positive control human umbilical vein endothelial cell (HUVEC) endothelial cell growth media (C).
Values are normalised to unconditioned MSC growth media and the number of MSCs is counted
at the end of the conditioning period. Photomicrographs showing representative examples of tube
formation in induced periosteum, non-union, HUVEC control, and unconditioned media treated wells
(C). All data IP (n = 6), NU (n = 7), C (four technical replicates). *** denotes p ≤ 0.001.
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4. Discussion
This study examined the MSC functional capacity, cellular content, histology, and vascularity of
tissue harvested from the site of atrophic NUs. Initially, we investigated the possibility that NU tissue
either lacked or had very low MSCs content. Our results show that this is not the case, in agreement
with previously published findings in this regard [26], and show that, following digestion, the MSC
frequency in NU tissue is substantially greater than that in BM aspirates [39] and comparable to IP [38],
as well as to enzymatically digested cancellous bone [46]. The possibility that MSCs isolated from
NU tissue were deficient in their ability to differentiate was then investigated. Contrary to previously
published data [26], we found no significant difference between NU- and BM-derived MSCs with
regards to in vitro differentiation capacity. Together, these results suggest that NU tissue contains a
large number of MSCs with no inherent defect in differentiation capacity in vitro.
Examination of the total cellular content of NU in comparison with IP tissue using flow cytometry
highlighted several important differences; NU tissue contains a greater proportion of cells expressing
markers specific to pericytes and endothelial cells and fewer lymphocytes. Although some caution
should be applied to analysis of cellular content based exclusively on measures of overall relative
percentages, this nevertheless suggests differences in the vascularity between these tissues, which were
confirmed in vivo. Histological examination revealed that, even though there are no differences in
regard to expression of key perivascular proteins, as their localisation in NU tissue closely replicated
that previously observed in IP tissue [38], NU tissue contained on average a greater number of much
smaller diameter blood vessels compared with IP tissue, which may have important implications for
the supply of oxygen and nutrients in these tissues. Histological examination also revealed striking
differences in the leukocytic content of NU and IP tissues leukocytes, which were largely absent in
NU. This confirms our flow cytometry findings and, furthermore, suggests tissue infiltration rather
than localisation within blood vessels as the cause of the observed higher number of lymphocytes in
IP tissue. One may, however, argue that the presence of lymphocytes in the IP could be secondary
to the foreign body reaction mounted against the Poly(methyl methacrylate)(PMMA) spacer, rather
than an increased permeability. While this is a possibility, because of the fact that the IP tissue was
harvested on average seven weeks after the cement implantation, at that stage, it is unlikely that an
inflammatory reaction was still active. It may well be that both the foreign body reaction and an
increased permeability contributed to this finding. Together, these results point to dissimilarities in
blood vessels number and size as key differences between these IP and NU tissues.
In order to ascertain what role, if any, MSCs may play in causing the differences in vascularity
observed in these tissues, we examined the transcriptional profile of MSCs derived from NU and
IP. Individual analysis of gene expression highlighted considerable differences in the expression of
several genes. The expression of FLT1, the gene encoding Fms-related tyrosine kinase 1, also known
as VEGFR-1, was significantly reduced in NU compared with IP tissue. FLT1 is a member of the
vascular endothelial growth factor receptor family [53,54] and exists as a soluble and membrane bound
form. FLT1 expression in periosteum-derived cells has been linked to osteogenesis [55], but is also
widely recognised for its role in angiogenesis. Homozygous deletion of flt-1 in mice is embryonically
lethal owing to uncontrolled accelerated endothelial cell differentiation, leading to the formation of
disorganised and ineffective vasculature [56]. Similarly, loss of flt-1 in developing vessels in vitro
results in an increased tip cell formation and sprout initiations, but a significant reduction in the
number of new stable conduits [57]. These effects were echoed in our study, where we observed a
greater proportion of endothelial cells, but a significant decrease in vessel diameter NU tissue, which
may indicate relative vessel immaturity.
Interestingly, expression of the gene encoding pleiotrophin (PTN) was significantly greater in
NU-derived MSCs. PTN is a secreted heparin-binding growth factor that may play a significant role in
bone remodelling either directly by influencing MSCs, or indirectly by influencing angiogenesis [58].
Increased angiogenesis, modulation of the vascular morphology, and deranged vessel perfusion and
functionality have been recently described in gliomas over-expressing PTN [59], in line with our
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data related to both vessel number and size, and different degrees of leukocyte infiltration in NU
tissue compared with IP tissue. Overall, our gene expression data are in line with previous studies
showing that fracture healing is impaired in adult PTN-over-expressing mice [60], perhaps as a result
of antagonizing the effect of BMP-2 [60,61].
Expression of the gene encoding angiopoietin-like 4 (ANGPTL4) was reduced in NU-derived
MSCs. ANGPTL4 promotes remodelling of the cartilage matrix during chondrogenic differentiation of
MSCs [62]; because expression of ANGPTL4 decreased in NU tissue-derived MSCs, this could indicate
defective endochondral ossification. Another immerging role of ANGPTL4 is in regulation of vascular
permeability [63–65]; this is interesting given the clear difference in leukocyte infiltration observed
between NU and IP tissues. Lack of leukocyte infiltration to NU tissue, specifically osteoclasts,
may result in decreased clearance of dead bone fragments and have significant implications for
disease pathogenesis.
Expression of the genes encoding WNT2 (wingless-type MMTV integration site family, member 2),
a member of the canonical Wnt signalling pathway, as well as FZD4 (frizzled class receptor 4) and
LRP5 (lipoprotein-related protein 5), which encode a receptor and co-receptor of the Wnt/β-catenin
signalling pathway, respectively, were reduced in NU tissue, although not significantly in the case of
LRP5. It is widely accepted that an increase in LRP5/6-mediated signalling leads to an increase in bone
mass [66–68]. Therefore, it is possible that the in vitro assays used in this study to assess osteogenesis
lack the subtlety to reflect changes to MSC Wnt signalling that in vivo would make a substantial
difference to bone formation. The increased level of SOX9 transcript, an important transcription factor
in chondrogenesis [69], supports this assertion. Differences in osteogenic culture conditions may
also explain the disparity between this study and the findings of Bajada et al., who observed loss of
osteogenic potential in MSCs originating from NU tissue [26].
Finally, a tube formation assay was performed to understand the functional consequences of
altered expression of MSC secreted factors associated with angiogenesis. Although media conditioned
with MSCs from NU tissue had a negligible effect on the early stages of angiogenesis, as measured by
this assay, MSCs conditioned media from IP tissue caused a striking reduction in angiogenesis. One
possible explanation for this could be that growth factors responsible for the relatively high baseline
angiogenesis seen in the unconditioned media were depleted in IP conditioned media. However,
in general, fewer MSCs were recorded at the end of the conditioning phase in IP compared with
NU, making this explanation unlikely. This leaves the possibility that MSCs from IP are actively
secreting factors that inhibit early vessel formation in this assay. This is consistent with our histology
observations that the number of both endothelial cells and pericytes were increased in NU tissue,
compared with IP tissue, but blood vessel diameters were significantly reduced in NU tissue compared
to IP tissue. Given that vascular flow is related to the fourth power of the vessel radius according
to Poiseuille’ equation our findings indicate substantial differences in vascular flow between IP and
non-union tissue, which will be manifold higher in the IP tissue.
These data appear to run contrary to the well-established idea that angiogenesis promotes bone
healing and that MSCs stimulate angiogenesis [19–21]. However, despite its inhibitory effect on the
early stages of angiogenesis, FLT-1 is integral to vessel stabilisation and spatial arrangement [70].
Therefore, we suggest that MSCs in IP tissue may be involved in guiding this process and that NU
MSCs either lack this ability or have not received the correct stimulus to initiate it. Regardless, the fact
that this phenotype persists in vitro for several rounds of culture expansion has wider implications in
the field of MSC therapy and suggests that careful consideration should be given to the angiogenic
phenotype of therapeutic MSCs. For example, MSCs exhibiting the phenotype of IP MSCs are unlikely
to be beneficial for therapies requiring rapid vascularisation of an avascular scaffold. Equally, in the
treatment of NU, MSCs that are able to stabilise an already existing vascular network and improve
blood flow would be beneficial. Additionally, understanding of the stimuli needed to switch MSCs
between these two phenotypes, particularly hypoxia, may have important implications for both
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regenerative medicine and cancer therapeutics, where MSCs are heavily implicated in driving tumour
angiogenesis [71–73].
One of the limitations of this study is its descriptive component. However, angiogenesis was
demonstrated at protein and functional levels in addition to the data obtained by qPCR. Moreover, the
samples harvested and analysed from patients represent a unique feature and contribute further to the
growing literature of non-union pathogenesis and IP research. They highlight the importance of a
cross-talk between local MSCs and endothelial cells in the formation and maturation of a functional
vascular network in the regenerating tissue. Future work would be desirable and should test the
candidate molecules using an animal model in order to further dissect the role of each individual
molecular component in the development of atrophic non-unions.
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